While the material that the company highlighted in today’s article produces has increased in price by 20% this year, the company has seen its stock price fall by double digits since the beginning of the year. So is this stock – which pays an attractive dividend – a buy? The author looks at why the shares of this company (and other producers of this material) have been driven down despite the fact that business is good – and why this could represent an opportunity for investors. For more, CLICK HERE.
Growth? Value? Size? When it comes to investing in factors, the author of today’s article acknowledges that “trying to determine which ones to invest in at a given time is an incredibly difficult undertaking.” He proceeds to examine which factors have outperformed historically at similar points in the market cycle to where we (presumably) are now: the late stages. What two factors have consistently been late-stage performers – and what factor is singled out as “the best of factors in the worst of times”? CLICK HERE.
The biotech highlighted in today’s article is the kind of stock that the author would normally advise investors to stay away from. In this case, however, he acknowledges that “this company could be worth quite a lot in the future, if it plays its cards right.” He proceeds to detail the company’s most interesting product – an anti-aging product that he believes has the potential to take it from micro-cap to industry leader (and which is drawing in a number of wealthy investors). For more, CLICK HERE
Today’s article highlights a number of potentially undervalued stocks in each and every sector – from Basic Materials to Healthcare to Utilities. In addition to these 32 specific stocks that may be worthy of further research and consideration, the article provides an overview of what equity analysts see as “the biggest themes and the best remaining investment opportunities in each sector.” To read more, CLICK HERE.
Gene editing – the ability to insert, delete and replace DNA – is a game-changing technology – and will be a very profitable one for the right companies. But what are those companies? Today’s article discusses three leading gene-editing companies worthy of attention, the specific diseases their therapies are intended to treat, how to invest in gene editing companies for the highest profit – and which biotech might have the edge when it comes to “the newest and best” gene-editing tool. For more, CLICK HERE.
“The turning of the calendar is…a perfect opportunity to evaluate your positions and diligently prepare your portfolio for success,” notes the author of today’s article – who proceeds to outline a number of tips for doing so. In particular, he emphasizes the role that exchange-traded funds can play – and recommends that those who have only moved a portion of their holdings to ETFs consider a more aggressive transition. For more – including what he points to as being one of the key benefits of ETFs (versus mutual funds) from a risk perspective – CLICK HERE.
While Canada is on track to fully legalize marijuana this year – and Canadian marijuana stocks on the whole stand to capitalize – not every company will necessarily be a winner and some Canadian pot stocks could be dangerous. Today’s article highlights one Canadian marijuana stock that – while up 367% over the last two years on expectations of growth – may not be such a “supreme” choice. CLICK HERE for more.
Whether 2018 brings a continuation of good times for the stock market – or proves to be the year in which the almost nine-year old bull market comes to an end – there are certain seemingly appealing stocks that investors may want to avoid. Today’s article shines a light on eight such stocks (as identified by top investment advisors), noting that “some of them appear to be value stocks, but their flawed fundamentals argue otherwise, while others have already enjoyed spectacular gains but now trade at excessive valuations.” For more, CLICK HERE
Hot tech stocks may have gotten the bulk of the attention in 2017, but today’s article observes that the best stock market trade last year didn’t even involve a specific stock. That trade? Shorting volatility, with the author noting that “two exchange-traded products betting against US stock volatility skyrocketed almost 200% in 2017 through Christmas, dwarfing returns for the absolute hottest mega-cap tech stocks.” But with a growing number of voices sounding the alarm over this strategy, is now the time to get in on the other side of the trade? CLICK HERE for more.
Out of the nearly 5,000 analysts tracked by the website TipRanks, the five who give their top stock picks for 2018 in today’s article have the most profitable track records based on “the average return and success rate of their buy-sell recommendations over the last year.” So which five specific stocks do these top Wall Street minds see outperforming in the coming year, how much upside do they see for them – and why? CLICK HERE.